A pilot study to evaluate the feasibility of using willingness to pay as a measure of value in cancer supportive care: an assessment of amifostine cytoprotection

This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. WTP as a measure of value in cancer supportive care is feasible and can easily be extended to other disease sites. Prophylactic amifostine in ovarian cancer patients receiving cyclophosphamide and cisplatin produces a situation of cost neutrality. This outcome was stable despite extremes in the cost of treating febrile neutropenia. However, the baseline results were sensitive to variations in respondents' maximum WTP, amifostine dosage and discount rate.